

UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Vignia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/654,323	09/01/2000	Michael R. Hayden	50110/004002	5878	
	/				
75	90 06/19/2003				
	ANT, ESQ. C/O	EXAMINER			
	'RNE, BAIN GILFILAN,	STEADMAN, DAVID J			
& OLSTEIN,					
6 BECKER RO		ARTINUT	D. DUD. W. C. C. C.		
ROSELAND, N	IJ 07068	ART UNIT	PAPER NUMBER		
			1652		
			DATE MAILED: 06/19/2003		

Please find below and/or attached an Office communication concerning this application or proceeding.

Offic Actio			Applicat	i n No.	Applicant(s)			
			09/654,3	323	HAYDEN ET AL.			
		Action Summary	Examin	r .	Art Unit			
				Steadman	1652			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply								
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status								
1)⊠	Responsi	ve to communication(s) filed on 2	22 April 2003					
2a) <u></u> ☐	This action	n is FINAL . 2b)⊠	This action is	non-final.				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.								
Dispositi	on of Clair		ier <i>⊑x paπe</i> C	<i>uayie</i> , 1935 C.D. 11, 4	53 O.G. 213.			
4)🛛	Claim(s)	1 <u>-51,57-84 and 92-94</u> is/are pendi	ing in the app	lication.				
	4a) Of the above claim(s) 1-49,57-79 and 92-94 is/are withdrawn from consideration.							
5)	5) Claim(s) is/are allowed.							
6)[6) Claim(s) is/are rejected.							
7)	7) Claim(s) is/are objected to.							
		0,51 and 80-84 are subject to res	triction and/o	r election requirement.				
Application Papers								
9) The specification is objected to by the Examiner.								
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.								
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). 11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.								
If approved, corrected drawings are required in reply to this Office action.								
12) The oath or declaration is objected to by the Examiner.								
Priority under 35 U.S.C. §§ 119 and 120								
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).								
		Some * c) None of:						
	1. Certified copies of the priority documents have been received.							
	2. Certified copies of the priority documents have been received in Application No							
Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.								
14)⊠ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).								
a) ☐ The translation of the foreign language provisional application has been received. 15)☑ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.								
Attachment(s)								
2) 🔲 Notice	e of Draftspers	es Cited (PTO-892) con's Patent Drawing Review (PTO-948) ure Statement(s) (PTO-1449) Paper No(s))		(PTO-413) Paper No(s) latent Application (PTO-152)			
	1 000							

Art Unit: 1652

DETAILED ACTION

Application Status

- [1] Claims 1-51, 57-84, and 92-94 are pending in the application.
- [2] Applicant's amendment to the specification, cancellation of claims 52 and 53 and amendment to claims 50, 51, 80, and 81 in Paper No. 20, filed April 22, 2003, is acknowledged.
- [3] It is noted that applicant requests cancellation of claims 54-56 in Paper No. 20. These claims have already been canceled in Paper No. 17.
- [4] Claims 1-49, 57-79, and 92-94 remain withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a non-elected invention, there being no allowable generic or linking claim.
- [5] Applicant is advised to identify polymorphisms by reference to a nucleic acid or amino acid sequence identified by a specific "SEQ ID NO:" in the claims.

Supplemental Election/Restrictions

- This supplemental restriction requirement is at the discretion of the examiner (see MPEP 802 and 37 CFR 1.142) and is deemed appropriate and necessary in view of the plurality of patentably distinct inventions encompassed by claims 50, 51, and 80-84.
- [7] Because claim 50 recites "at least one polymorphism", restriction to one OR a specific combination of the following inventions is required under 35 USC 121:
 - Claim(s) 50, 51, and 80-84, drawn to a method for determining a propensity for developing a disease or condition by detecting a Q597R polymorphism in an ABC1 protein, classified in class 435, subclass 6.
 - II. Claim(s) 50, 51, and 80-84, drawn to a method for determining a propensity for developing a disease or condition by detecting a ΔL693 polymorphism in an ABC1 protein, classified in class 435, subclass 6.

Art Unit: 1652

Page 3

- III. Claim(s) 50, 51, and 80-84, drawn to a method for determining a propensity for developing a disease or condition by detecting an R909X polymorphism in an ABC1 protein, classified in class 435, subclass 6.
- IV. Claim(s) 50, 51, and 80-84, drawn to a method for determining a propensity for developing a disease or condition by detecting a T929I polymorphism in an ABC1 protein, classified in class 435, subclass 6.
- V. Claim(s) 50, 51, and 80-84, drawn to a method for determining a propensity for developing a disease or condition by detecting a M1091T polymorphism in an ABC1 protein, classified in class 435, subclass 6.
- VI. Claim(s) 50, 51, and 80-84, drawn to a method for determining a propensity for developing a disease or condition by detecting an IVS24+1 G→C polymorphism in an ABC1 protein, classified in class 435, subclass 6.
- VII. Claim(s) 50, 51, and 80-84, drawn to a method for determining a propensity for developing a disease or condition by detecting a C1477R polymorphism in an ABC1 protein, classified in class 435, subclass 6.
- VIII. Claim(s) 50, 51, and 80-84, drawn to a method for determining a propensity for developing a disease or condition by detecting a Δ(E,D)1893,94 polymorphism in an ABC1 protein, classified in class 435, subclass 6.
- IX. Claim(s) 50, 51, and 80-84, drawn to a method for determining a propensity for developing a disease or condition by detecting a R2144X polymorphism in an ABC1 protein, classified in class 435, subclass 6.
- X. Claim(s) 50, 51, and 80-84, drawn to a method for determining a propensity for developing a disease or condition by detecting a ΔC6825→2145X polymorphism in an ABC1 protein, classified in class 435, subclass 6.

Art Unit: 1652

- **XI.** Claim(s) 50, 51, and 80-84, drawn to a method for determining a propensity for developing a disease or condition by detecting a P2150L polymorphism in an ABC1 protein, classified in class 435, subclass 6.
- XII. Claim(s) 50, 51, and 80-84, drawn to a method for determining a propensity for developing a disease or condition by detecting a CTC6952-4TT→2203X polymorphism in an ABC1 protein, classified in class 435, subclass 6.
- [8] The inventions are distinct, each from the other because:
- [9] Each of the ABC1 polymorphic proteins of Groups I-XII is structurally distinct and thus the methods of Groups I-XII are independent as they utilize different products.
- [10] MPEP § 803 sets forth two criteria for restricting between patentably distinct inventions 1) the inventions must be independent or distinct and 2) there must be a serious burden on the examiner. MPEP § 803 states, "For purposes of the initial requirement, a serious burden on the examiner may be *prima facie* shown if the examiner shows by appropriate explanation either separate classification, separate status in the art, or a different field of search as defined in MPEP § 808.02". Because the inventions of Groups 1-XII are distinct for the reasons given above and each of the inventions requires a separate patent and non-patent literature and sequence search, restriction for examination purposes is proper.
- [11] It is noted that claims 50, 51, and 80-84 will be examined only to the extent the claims read on the elected one OR specific combination of polymorphisms.
- [12] Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).
- [13] Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Art Unit: 1652

Any inquiry concerning this communication or earlier communications from the examiner should be directed to David Steadman, whose telephone number is (703) 308-3934. The Examiner can normally be reached Monday-Thursday from 6:30 am to 5:00 pm. If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Ponnathapura Achutamurthy, can be reached at (703) 308-3804. The FAX number for this Group is (703) 308-4242. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Art Unit receptionist whose telephone number is (703) 308-0196.

David J. Steadman, Ph.D. Patent Examiner
Art Unit 1652

Page 5